Citius Oncology (CTOR) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Citius Oncology (CTOR) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 54.7% versus a loss of 63.6%. Milestone Pharmaceuticals is the larger company by market cap ($91.1 million vs $89.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTOR | MIST |
|---|---|---|
| Share price | $0.85 | $0.732 |
| Market cap | $89.90M | $91.13M |
| 1-day change | -0.70% | -3.32% |
| YTD return | -14.90% | -62.51% |
| 1-year return | -54.73% | -63.60% |
| 5-year return | — | -87.17% |
| EPS (TTM) | $-0.48 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.25 | $3.06 |
| 52-week low | $0.491 | $0.7228 |
| Distance from 52-week high | -62.22% | -76.08% |
| Average volume | 99.72K | 1.39M |
| Shares outstanding | 105.76M | 124.50M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CTOR vs MIST FAQ
Which is bigger, Citius Oncology or Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $91.13M compared with $89.90M for Citius Oncology (CTOR).
Which stock has performed better over the past year, CTOR or MIST?
CTOR returned -54.73% over the past 12 months, compared with -63.60% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Citius Oncology and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.